Case Report

Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome

Salem M. Tos a,*, Bilal Nabeel Alqam a, Narmeen Giacaman a, Mohammad G. Ibdah a, Mahmoud M.M. Gabajah a, Abdallah Altell b

a Al-Quds University, College of Medicine, Palestine
b Istishari Arab Hospital, Ramallah, State of Palestine, Palestine

ABSTRACT

Background: Netherton syndrome is a rare autosomal recessive disease that presents with a triad of symptoms which include atopic diathesis, ichthyosis linearis circumflexa, and hair shaft abnormality termed “Bamboo Hair”. Netherton syndrome patients can develop cutaneous squamous cell carcinoma (cSCC) in unusually young age. Pembrolizumab is the first line treatment for locally advanced and recurrent/metastatic cSCC.

Case presentation: A 44-year-old man with a history of Netherton syndrome and multiple skin squamous cell carcinoma was diagnosed with locally advanced and recurrent/metastatic cSCC two years ago. He was started on Pembrolizumab as a treatment for his cSCC. The immunotherapy course was well tolerated with no significant side effects including the expected immune related adverse events seen in patients treated with this medication. PET/CT scan showed significant regression of his disease consistent with partial response according to the response evaluation criteria in solid tumors.

Discussion: Incurable and recurrent cSCC tends to metastasize, leading to an extremely poor long-term prognosis, and the treatment options for locally advanced or metastatic disease are few. Pembrolizumab, an immune checkpoint inhibitors (ICIs) showed a benefit in patients with various tumors including squamous cell carcinoma, but using this drug which is working by enhancing the immunity against tumor in patient with altered immunity like Netherton syndrome was a bit of a challenge, in terms of both effectiveness and safety.

Conclusion: Pembrolizumab had a effective and safe treatment profile when it was used as a monotherapy for treating a Netherton syndrome patient diagnosed with locally advanced and recurrent/metastatic cSCC.

1. Introduction

Cutaneous squamous cell carcinoma (cSCC) is a cancer that arises due to malignant proliferation of epidermal keratinocytes [1]. It is considered the second most common non-melanoma skin cancer after basal cell carcinoma [2] and as for treatment it can be surgical or non-surgical with photodynamic therapy, topical with imiquimod or 5-fluorouracil, and laser ablation and immunotherapy [3]. Pembrolizumab, a PD-1 inhibitor, is a medication used in cancer immunotherapy that can be used as a first-line treatment for cSCC and has demonstrated an acceptable safety profile and clinically meaningful response when it was used as a monotherapy for locally advanced and recurrent/metastatic cSCC [4].

Netherton syndrome is a type of congenital ichthyosis, a rare autosomal recessive disease. It is caused by loss-of-function mutations in SPINK5 [5]. It is clinically characterized by a triad of symptoms that include atopic diathesis (elevated IgE), congenital ichthyosiform erythroderma (CIE) or ichthyosis linearis circumflexa (ILC), and hair shaft abnormality termed “Bamboo Hair” [6]. Patients with congenital ichthyosis including Netherton syndrome can develop cutaneous SCC in unusually young age [7].

There is absent data addressing treatment options for patients with Netherton syndrome and advances in cSCC. In the current paper, we present such a rare case treated with Pembrolizumab and report data with the outcome and tolerability for that patient. And Advanced CSCC patients are associated with a higher average cost than patients with resectable CSCC [8].

This case report has been reported in line with the SCARE Criteria [9].

2. Case presentation

A 44-year-old man, with a history of Netherton syndrome and multiple skin squamous cell carcinoma, came to outpatient clinic...
complaining of dry cough, dyspnea and squeezing chest pain of 3-month duration. The patient was born with scaly erythroderma, sparse hair growth except on the head and neck and seasonal allergy with elevated IgE level. He is a product of non-consanguineous healthy parents and family history revealed that he has a brother with a known case of Netherton syndrome.

The patient uses topical corticosteroid cream applied to his whole body daily after taking a shower to prevent the itching and reduce the redness since he was 13 years old (Fig. 1). Additionally, he takes oral antihistamine for his seasonal allergy.

The patient also has a long history of skin tumors. At the age of 36-years-old, the first mass appeared on his right lateral neck, but he ignored it until the age of 41-years-old as it became very ugly looking. He underwent surgical excision with flap rotation and free margins and histological evaluation of the skin mass revealed that it was cSCC. No further management or investigations were done. Since then and a year after, two local recurrent masses developed and were treated in the same manner.

Three months after the last local recurrence, the patient came to us complaining of dry cough that was severe enough to cause left direct inguinal hernia, dyspnea and squeezing chest pain. Meanwhile, during that year he had lost 10 kg without any changes in his diet.

Chest x-ray revealed well defined irregular rounded opacity measuring about 4.3 × 5 cm seen at the left lower lung zone, surrounded by a regional area of consolidation (Fig. 2).

Chest computed axial tomography (CT) scan performed showed three pulmonary mass lesions, the largest one measuring 8.7 × 8 × 6.5 cm in the left lower lobe extending to the anterior basilar segment and to the left infra-hilar region. The other two pulmonary lesions were in the left lower lobe within the medial and lateral base of segments, the larger of these measuring up to 4.2 cm in diameter. There was no evidence of any mass lesion in the right lung field nor pericardial or pleural effusion (Fig. 3A).

Furthermore, a bronchoalveolar lavage and biopsy were performed

Fig. 1. A: Ichthyosiform erythroderma (Generalized erythroderma and greasy, yellow-to-white scale on face and neck). B, C, D: Generalized erythroderma involving all body. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 2. Chest-XR revealed well defined irregular rounded opacity with surrounding consolidation at the left lower lung zone.
revealing moderately differentiated SCC which were negative for both Thyroid transcription factor-1 (TTF-1) and Napsin A. A brain MRI showed right maxillary sinus mass extending to the nasal cavity and two small osteolytic skull lesions (Fig. 4).

He was started on Pembrolizumab as a treatment for his metastatic SCC. Till now, he had received 20 cycles of pembrolizumab (200 mg intravenously), fixed 3 weeks apart. During his treatment he hadn’t develop any immune related adverse events and improving clinically after the third cycle. His cough and dyspnea were much better, and his appetite and weight improved during the treatment period.

In conclusion, the immunotherapy course was well tolerated with no significant side effects in the patient and the PET scan and CT scan done at 6 and 12 months after starting pembrolizumab showed significant regression of his disease consistent with partial response according to the Response Evaluation Criteria In Solid Tumors (RECIST v. 1.1). At the time of this report, pembrolizumab treatment is still ongoing, and he remains free of progression almost 15 months after starting pembrolizumab (Fig. 3B).

3. Discussion

Inherited ichthyoses are rare inherited disorders with skin manifestations caused by mutations in the genes involved in epidermal development. They include many diseases such as keratitis–ichthyosis–deafness (KID) syndrome, autosomal recessive congenital ichthyosis and Netherton syndrome. These patients seem to be prone to skin malignancies, including SCC, at an unusually young age. Hence, these patients are recommended to have routine skin cancer surveillance [10].

The exact mechanism of carcinogenesis in Netherton syndrome (NS) is unclear. It may be related to chronic infection, like HPV, chronic inflammation of the skin, or can be related to the use of UV light and immunosuppressive medication. A retrospective cohort study published in 2000 [11], aimed to study the presence of HPV infection in different skin lesions of three male NS patients and to investigate a possible association between HPV and malignancies in NS, the results showed that seven of 22 (31%) biopsies of the three NS patients were positive for HPV DNA, it also revealed that one patient who had five lesions which were diagnosed as cSCC, three of these five cSCC were positive for HPV. However, the patient’s polymerase chain reaction (PCR) did not detect any HPV DNA in samples taken from the SCC masses.

Several findings of immunological abnormalities in NS, including dysfunction of memory B cells and natural killer cells, and mutations of SPINK5 that may affect T cell differentiation leading to IgE overproduction [12]. The use of immunosuppressive medication in already immunosuppressed patients has been also associated with an increased incidence of skin cancers [13,14]. Topical steroid cream was used to reduce the redness and itchiness in the patient so it could be a possible cause for the masses that were found.

The patient who was a known case of Netherton syndrome wasn’t following any routine skin cancer surveillance and was ignorant towards the growths on his skin that later appeared to be cSCC which had already metastasized to his lung, maxillary sinus, and skull bones. He was started on Pembrolizumab for his recurrent and metastatic cSCC.

Non-melanoma skin cancer (NMSC) constitutes one-third of all malignancies. NMSC includes basal cell carcinoma (80%) and cSCC (20%). Although cSCC represents about only 20% of NMSC, it has the ability to metastasize which is considered a threat and it is worth to mention that 20% of skin cancer deaths are attributable to cSCC [15]. Most patients with cSCC can be treated with surgical resection of the tumor.

Unfortunately, incurable and recurrent cSCC tends to metastasize leading to an extremely poor long-term prognosis of metastatic disease, and the treatment options for locally advanced or metastatic disease are few (they include platinum-based chemotherapy and off label use of cetuximab in addition to radiotherapy) [16]. The response usually lasts a
short time, often accompanied by significant side effects, especially in elderly and frail subjects. For this condition, the 10-year survival rate is less than 20% for patients having regional lymph node metastasis and less than 10% for those patients having distant metastasis [17].
cSCC has a high tumor mutation burden (TMB) that results from UV radiation-induced DNA damage. Due to their high TMB, cSCC may be responsive to immunotherapy as treatment [4].
Pembrolizumab is an engineered humanized IgG4 mAb against PD-1 [18], and it is used as a new emerging tumor treatment known as an anti-cancer, being part of the family classified as immune checkpoint inhibitors (ICIs) [19]. It showed a benefit in patients with various tumors (e.g., advanced non-small-cell lung cancer), melanoma, urothelial carcinoma, squamous cell carcinoma of head and neck (SCCHN), and Merkel cell carcinoma [20–24].
Pembrolizumab showed clinically meaningful and durable antitumor activity with a manageable safety profile in patients with R/M cSCC based on the first interim analysis (IA). Thus, Pembrolizumab was approved by the USA FDA for R/M cSCC that is not curable by surgery or radiation [25].
In addition to its antitumor effect, it can potentially provoke immune-related adverse events (irAEs) across any organ as and these are major side effects of this drug, including skin, liver, gastrointestinal and endocrine inflammation [26,27]. A cohort study published in 2016 [26], involving 496 patient were screened for anti-PD-1 AEs. In total, 242 rare or unexpected side effects of nivolumab and pembrolizumab were documented in 138 patients (27.8%). Neurological, respiratory, musculoskeletal, cardiac, ocular and haematopoietic AEs occurred in 77 of the 138 patients. Some side effects are reported for the first time like cardiac arrhythmia, paresis, aphasia, a meningo-(radiculitis), and parakinsonoid syndrome. Furthermore, rare side effects like myasthenia gravis and polyradiculitis are also reported. however, in our patient, none of these events occurred after 16 months of using the anti-PD-1 drug even though he has immunological dysfunction as he is a Netherton syndrome patient.
To the best of our knowledge, this is the first case of using pembrolizumab for recurrent and metastatic cutaneous SCC in a patient with Netherton syndrome.

4. Conclusion
Pembrolizumab monotherapy, which enhances the immune response against tumor, demonstrated effective antitumor activity, clinically meaningful response, and acceptable safety parameters in primarily middle-aged man with metastatic cSCC, in spite the fact that the patient had already immunity dysfunction since birth (Netherton syndrome in this case) due to uncertain mechanism, and also elevated IgE and eosinophils level due to seasonal allergy.
This is a first case of using Pembrolizumab for metastatic cSCC in patient with Netherton syndrome who uses topical steroid for his skin changes.

Ethical approval
The study is exempt from ethical approval in our institution.

Sources of funding
No funding or grant support.

Author contributions
Study concept or design: Abdallah alteff.
Writing the manuscript: Salem M. Tos, Bilal Nabeel Alqam, Narmeen Giacaman, Mohammad G. Ibdah and Mahmoud M. M. Gabajah.
Review & editing the manuscript: Salem M. Tos, Bilal Nabeel Alqam.

Registration of research studies
Not applicable.

Guarantor
Dr. Salem M. Tos.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review
Not commissioned, externally peer reviewed.

Declaration of competing interest
The authors declare no conflicts of interest.

Acknowledgments
The authors thank the patient and his family.

References
[1] J.R. Kallini, N. Hamed, A. Khachemoune, Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends, Int. J. Dermatol. 54 (2) (2015 Feb) 130–140, https://doi.org/10.1111/ijd.12553. Epub 2014 Nov 27. PMID: 25428226.
[2] V. Samarasinge, V. Madan, Nonmelanoma skin cancer, J. Cutan. Aesthetic Surg. 5 (1) (2016 Jan) 3–10, https://doi.org/10.1143/0974-2077.94323. PMID: 22557848; PMCID: PMC339125.
[3] A. Gombalia, C. Carrera, Squamous cell carcinoma: an update on diagnosis and treatment, Dermatol. Pract. Concept. 10 (3) (2020) e2020066, https://doi.org/10.5862/dpc.1003422. Jun 29, 2020; PMID: 32642314; PMCID: PMC7919751.
[4] B.G.M. Hughes, E. Munoz-Couselo, L. Mortier, Guttmner R. Bratland A, O. Rosdhy, R. González Mendoza, J. Schachter, A. Arance, F. Grange, N. Meyer, A. Jodhi, S. Billan, P. Zhang, B. Gumuscu, R.F. Swaby, J.J. Grob, Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial, Ann. Oncol. 32 (10) (2021 Oct) 1276–1285, https://doi.org/10.1016/j.annonc.2021.07.008. Epub 2021 Jul 20. PMID: 34293460.
[5] A. Hovanianian, Netherton syndrome: skin inflammation and allergy by loss of protease inhibition, Cell Tissue Res. 351 (2) (2013 Feb) 289–300, https://doi.org/10.1007/s00441-013-1556-1. Epub 2013 Jan 24. PMID: 23344365.
[6] M.E. Herz-Ruelas, S. Chavez-Alvarez, J.J. Garza-Chapa, J. Ocampo-Candiani, V. A. Cab-Morales, D.E. Kubelis-López, Netherton syndrome: case report and review of the literature, Skin Appendage Disord 7 (5) (2021 Aug) 346–350, https://doi.org/10.1159/000514699. Epub 2021 Jun 15. PMID: 34604321; PMCID: PMC8436607.
[7] K. Natag, M. Akiyama, H. Shimizu, Malignant skin tumours in patients with inherited ichthyosis, Br. J. Dermatol. 165 (2) (2021) 263–268, https://doi.org/10.1111/j.1365-2133.2011.10391.x.
[8] A. Marcellus, C. Bini, K. Peris, P.A. Asciento, F.S. Mennini, Cost of illness of cutaneous squamous cell carcinoma (CSCC), Gritta [Internet] 7 (1) (2020) 146–153. Dec. 28 [cited 2022 Jul. 25].
[9] R.A. Agha, T. Tranchi, C. Sohrabi, G. Mathew, A. Kerwan, SCARE Group, The SCARE 2020 guideline: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020 Dec) 226–230, https://doi.org/10.1016/j.ijnssu.2020.10.034. Epub 2020 Nov 9. PMID: 33181558.
[10] K. Natag, M. Akiyama, H. Shimizu, Malignant skin tumours in patients with inherited ichthyosis, Br. J. Dermatol. 165 (2) (2011 Aug) 263–268, https://doi.org/10.1111/j.1365-2133.2011.10381.x. Epub 2011 Jul 11. PMID: 21517795.
[11] F. Weber, P.G. Fuchs, H.J. Pfister, H. Himmer, P. Fritsch, R. Hoepfl, Human papillomavirus infection in Netherton’s syndrome, Br. J. Dermatol. 144 (5) (2001) 1044–1049.
[12] D. Van Gysel, H. Koning, M.R. Baert, H.F. Savelkoul, H.J. Neijens, A.P. Oranje, Clinico-immunological heterogeneity in Comel-Netherton syndrome, Dermatology 202 (2001) 99–107.
[13] I. Marcellus, R.S. Stern, Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study, Lancet 29 (358) (2001) 1042–1045.
[14] A.D. Ormerod, Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br. J. Dermatol. 153 (2005) 701–705.
[15] B. Gurney, C. Newlands, Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma, Br. J. Oral Maxillofac. Surg. 52 (4) (2014) 294–300.

[16] S. Venkatesh, A. Al-Haseni, D. Sahni, Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab, BMJ Case Reports CP 12 (2019), e229915.

[17] M.L.M. van Baar, A.D. Guminski, P.M. Ferguson, L.K. Martin, Pembrolizumab for cutaneous squamous cell carcinoma: report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation, JAAD Case Rep 5 (6) (2019) 491–494, https://doi.org/10.1016/j.jdcr.2019.04.006. May 25, PMID: 31193588; PMCID: PMC6536769.

[18] A. Akinleye, Z. Rasool, Immune checkpoint inhibitors of PD-L1 as cancer therapeutics, J. Hematol. Oncol. 12 (1) (2019) 92, https://doi.org/10.1186/s13045-019-0779-5. Published 2019 Sep. 5.

[19] J. Rogado, J.M. Sánchez-Torres, R. Arranz, A. Lorenzo, P. Gullón, O. Donnay, M. Afromos, P. Coster, J. Aspa, A. Alfranca, R. Mondéjar, R. Colomer, Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients, Eur. J. Cancer 109 (2019 Mar) 21–27, https://doi.org/10.1016/j.ejca.2018.10.014. Epub 2019 Jan 22. PMID: 30682460.

[20] M. Reck, D. Rodriguez-Arroyo, A.G. Robinson, et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med. 375 (2016), 1823e33.

[21] C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, et al., Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med. 372 (2015). Jun 25, 2521e32.

[22] J. Bellmunt, R. de Wit, D.J. Vaughn, Y. Fridet, J.L. Lee, L. Fong, Pembrolizumab as second-line therapy for advanced urethelial carcinoma, N. Engl. J. Med. 376 (11) (2017), 1015c26.

[23] J. Bauml, T.Y. Seiwert, D.G. Pfister, et al., Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC), J. Clin. Oncol. 35 (2016), 1542e9.

[24] P.T. Nghiem, S. Bhatia, E.J. Lipson, et al., PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma, N. Engl. J. Med. 374 (2016), 2542e52.

[25] B.G.M. Hughes, E. Munoz-Couselo, L. Mortier, Gutzmer R. Bratland Â, O. Rosjdy, R. González Mendoza, J. Schachter, A. Arance, F. Grange, N. Meyer, A. Joshi, S. Billan, P. Zhang, B. Gumuscu, R.F. Swaby, J.J. Grob, Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial, Ann. Oncol. 32 (10) (2021 Oct) 1276–1285, https://doi.org/10.1016/j.annonc.2021.07.008. Epub 2021 Jul 20. PMID: 34293460.

[26] L. Zimmer, S.M. Goldinger, L. Hofmann, C. Loqui, S. Ugurel, I. Thomas, M. I. Schmidigen, R. Gutzmer, J.S. Utkal, D. Göppert, J.C. Hassel, F. Meier, J. K. Tietze, A. Forchacher, C. Weihaupt, M. Leverkus, R. Wahl, U. Dietrich, C. Garbe, M.C. Kirchberger, T. Eigentler, C. Berking, A. Eschierich, A.M. Knackhardt, D. Schadendorf, G. Schuler, R. Dummer, L.M. Heinzerling, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, Eur. J. Cancer 60 (2016 Jun) 210–225, https://doi.org/10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13. PMID: 27083435.

[27] E. Eranško, M. Iander, M. Tuomiranta, et al., Immune cell phenotype and functional defects in Netherton syndrome, Orphanet J. Rare Dis. 13 (2018) 213, https://doi.org/10.1186/s13023-018-0956-6.